

DRUG NAME: ANASTROZOLE**SYNONYM(S):** IUPAC; ZD1033; ICI D1033**COMMON TRADE NAME(S):** ARIMIDEX® (notice of compliance,¹ April 1997; patent expires² October 2012)**CLASSIFICATION:** Aromatase inhibitor*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Anastrozole is a reversible (Type II), nonsteroidal aromatase inhibitor. Aromatase catalyzes the final and rate-limiting step in the conversion of androgens to estrogens in peripheral tissues. This occurs mainly in adipose tissue, but also in normal and malignant breast tissues, and provides the main source of estrogen in postmenopausal women. The goal of hormone therapy in breast cancer is to deprive tumour cells of estrogens, which are implicated in the development or progression of tumours.^{3,4} Maximal estrogen suppression is produced by a 1mg dose.⁵ Estrogen suppression is maintained for up to 6 days after discontinuing anastrozole.⁶ Differences in the mechanism of action may contribute to the apparent lack of cross-resistance between steroidal (eg, exemestane) and nonsteroidal (eg, anastrozole and letrozole) aromatase inhibitors.⁷ Highly selective blockade of aromatase does not interfere with the production of other steroids (eg, adrenal corticosteroids, aldosterone)⁶ or thyroid stimulating hormone.⁸ Anastrozole does not have progestogenic, androgenic or estrogenic activity.^{6,8}

PHARMACOKINETICS:

Interpatient variability	no information found	
Oral Absorption	rapidly and almost completely absorbed ⁹ ; food reduces absorption rate	
	time to peak plasma concentration	within 2 h
Distribution	steady-state plasma level is 3-4 times higher than the level after a single dose and achieved after 7-9 days of once daily oral dosing ⁶	
	cross blood brain barrier?	no information found
	volume of distribution	no information found
	plasma protein binding	40%
Metabolism	primarily in the liver via N-dealkylation, hydroxylation and glucuronidation	
	active metabolite(s)	none
	inactive metabolite(s)	triazole, glucuronides, hydroxy-anastrozole
Excretion	biliary and renal excretion	
	biliary	85%
	urine	11%
	terminal half life	50 h (range, 30-60 h) ¹⁰
	clearance	no information found
Gender	no information found	
Elderly	no clinically significant differences	
Children	no information found	
Ethnicity	no clinically significant differences in pharmacodynamics and pharmacokinetics between Asian and white postmenopausal women ¹¹	

Adapted from reference 8 unless specified otherwise.

USES:**Primary uses:***Breast cancer¹²⁻¹⁶

*Health Canada Therapeutic Products Programme approved indication

No pediatric indications.

SPECIAL PRECAUTIONS:**Carcinogenicity:** No information found.¹⁷**Mutagenicity:** Not mutagenic in Ames test and in mammalian *in vitro* mutation test. Anastrozole is clastogenic in *in vitro* and *in vivo* chromosome tests.¹⁷**Fertility:** No information found.¹⁷**Pregnancy:** FDA pregnancy category D¹⁷ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (eg, the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).**Breastfeeding** is not recommended due to potential secretion into breast milk.⁸**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.¹⁸

ORGAN SITE	SIDE EFFECT	ONSET		
Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks) D = delayed (weeks to months); L = late (months to years)				
cardiovascular (general)	hypertension (3-9%) ¹⁹		E	D
	ischemic cardiovascular disease (3-4%) ²⁰⁻²²			L
	peripheral edema (8-10%)		E	
	thromboembolism (2-4%) ²⁰⁻²²			D
	vasodilatation (25-35%) ¹⁹		E	
constitutional symptoms	asthenia (16-18%)		E	
	fatigue/tiredness (19%) ²⁰⁻²²		E	
	sweating (2-4%) ¹⁹		E	
	weight gain (13%) ¹⁴			D
dermatology/skin	hair thinning (rare)		E	D
	rash (6-10%) ¹⁹		E	D
endocrine	hot flashes (13-35%) ²⁰⁻²²	I	E	
gastrointestinal	emetogenic potential: nonemetogenic ¹⁴		E	
	anorexia (5-7%)		E	
	constipation (9%)		E	D

ORGAN SITE	SIDE EFFECT	ONSET		
<p>Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks) D = delayed (weeks to months); L = late (months to years)</p>				
	diarrhea (8%)		E	D
	dry mouth (6%)		E	
	nausea (11-19%) ²⁰⁻²²	I	E	
	vomiting (8-13%) ²⁰⁻²²	I	E	
hemorrhage	vaginal bleeding (1-5%) ²⁰⁻²²		E	
hepatic	elevated liver function tests (infrequent) ¹⁸			D
lymphatics	lymphoedema (9%) ¹⁹			D
metabolic/laboratory	hypercholesterolemia (7%) ¹⁹			L
musculoskeletal	arthritis (14%) ^{19,23}			L
	arthrosis (6%) ²³		E	
	fractures (6-11%) ¹⁹⁻²²			L
	hypertonia (3%)		E	
	osteoporosis (7%) ^{22,23}			L
neurology	anxiety (5%) ¹⁹			D
	depression (5-11%) ¹⁹			D
	dizziness (6%)		E	
	insomnia (6-9%) ¹⁹		E	
	ischemic cerebrovascular events (1-2%) ²⁰⁻²²			L
	neuropathy, sensory (5%)		E	
ocular/visual	cataracts (4-6%) ²⁰⁻²²			L
pain	abdominal pain (8%)		E	
	arthralgia/myalgia (5-36%) ^{19,22-24}		E	
	back pain (10-12%)		E	D
	bone pain (5-11%) ²³		E	D
	breast tenderness (7%) ¹⁹		E	D
	chest pain (5-7%)		E	
	headache (9-14%)		E	
	pelvic pain (5%)		E	D
pulmonary	cough (8-11%)		E	D
	dyspnea (10%)		E	D
	pharyngitis (6-12%) ¹⁹		E	
renal/genitourinary	vaginal discharge (2-3%) ²⁰⁻²²		E	
	vulvovaginitis (6%) ¹⁹		E	
sexual/reproductive function	vaginal bleeding (see under "hemorrhage")		E	
	vaginal dryness (3%)		E	
syndromes	flu-like symptoms (7%)		E	
	tumour flare (3%)		E	

Adapted from reference 8 unless specified otherwise.

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
antipyrine	no significant effects on antipyrine pharmacokinetics		
cimetidine	no significant effects on anastrozole pharmacokinetics		
estrogen (estrogen replacement therapy, Premarin, C.E.S., Estracomb, Estraderm)	may interfere with therapeutic effect of anastrozole	estrogen can counter the estrogen suppression effect of anastrozole	see below
warfarin	no significant effects on warfarin pharmacokinetics and pharmacodynamics		
tamoxifen ²⁵	no significant effects on tamoxifen pharmacokinetics; tamoxifen does not appear to affect estrogen suppressant effect of anastrozole		

Adapted from reference 19 unless specified otherwise.

Anastrozole is a weak inhibitor of cytochrome P450 *in vitro* and not expected to have clinically significant interactions with drugs metabolized by cytochrome P450.²⁶

Estrogen use with anastrozole: use other options for conditions in which estrogen is indicated. If estrogen is used, prescribe the lowest dose to relieve symptoms, monitor patient carefully and consider short term use.²⁷ For vaginal complaints such as dyspareunia, dryness and sexual dysfunction, topical estrogen may be considered. Estring produces a local effect with systemic levels measurable only for the first 24 hours of the three month ring. Premarin cream can be used but may have variable systemic levels related to the absorption through the vaginal tissues. The lowest dose to relieve symptoms should be used.²⁸

SUPPLY AND STORAGE:

Tablet: 1 mg; inactive ingredient includes lactose. Store at room temperature.⁸

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated.

Adults:

BCCA usual dose noted in ***bold, italics***

Oral: ***1 mg PO once daily.***
Administer with food or on empty stomach.⁸

Dosage in renal failure: no adjustment required⁸

Dosage in hepatic failure: No dose adjustment is required in mild to moderate hepatic dysfunction. Dosing studies have not been done in patients with severe hepatic dysfunction.⁸

BCCA usual dose noted in ***bold, italics***

Dosage in dialysis: no information found

REFERENCES:

1. Health Canada Therapeutic Products Programme. Notices of compliance (NOC)-Drugs. Available at: <http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/noc-drugs.html>. Accessed August 30, 2000.
2. Health Canada Therapeutic Products Programme. Patent register. Available at: <http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/patents.html>. Accessed August 30, 2000.
3. Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. *Drugs* 1999;58(2):233-55.
4. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. *Endocrine-Related Cancer* 1999;6(1):75-92.
5. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. *British Journal of Cancer* 1996;74(8):1286-91.
6. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): selective, potent inhibitor of aromatase in postmenopausal female volunteers. *British Journal of Cancer* 1996;73:543-548.
7. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. *European Journal of Cancer* 2000;36(8):976-82.
8. Astrazeneca. Arimidex product monograph. Mississauga, Ontario; 7 June 2000.
9. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. *Breast Cancer Research and Treatment* 1994;30:103-111.
10. Higa GM, Alkhoury N. Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer. *American Journal of Health-System Pharmacy* 1998;55(5):445-52.
11. Dowsett M, Donaldson K, Tsuboi M, et al. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. *Cancer Chemotherapy and Pharmacology* 2000;46(1):35-9.

12. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer [see comments]. *European Journal of Cancer* 1996;32A(3):404-12.
13. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. *Cancer* 1997;79(4):730-9.
14. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. *Journal of Clinical Oncology* 1996;14(7):2000-11.
15. Buzdar A, Nabholz JM, Robertson JF, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women? Combined analysis from two identically designed multicenter trials. *Proceedings of the American Society of Clinical Oncology* 2000;19:154a (abstract 609d).
16. Baum M, Houghton J. Arimidex, tamoxifen alone or in combination adjuvant trial in postmenopausal breast cancer. *European Journal of Cancer* 1998;34(Suppl 1):99.
17. Anastrozole. USP DI. Volume 1. Drug information for the health care professional. 20th ed. Englewood, Colorado: Micromedex, Inc.; 2000.
18. Susan Ellard MD. Personal Communication. BC Cancer Agency Breast Tumour Group; 14 January 2005.
19. AstraZeneca. Arimidex product monograph. Mississauga, Ontario; 16 June 2004.
20. The ATAC Trialists' Group. Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer. *Cancer* 2003;98:1802-10.
21. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002;359(9324):2131-39.
22. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* Published online December 8, 2004;364(9451).
23. Craig Shankar. Personal Communication. Medical Information Specialist AstraZeneca Canada; 9 November 2004.
24. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. *Cancer* 1998;83(6):1142-52.

25. Dowsett M, Tobias JS, Howell A, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. *British Journal of Cancer* 1999;79(2):311-5.
26. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 1997;25(5):598-602.
27. BC Cancer Agency Breast Tumour Group. *Cancer Management Guidelines: Breast Follow-up - Hormone replacement therapy after a diagnosis of breast cancer*. 2000 March 1.
28. Brian Norris MD. Personal Communication. BC Cancer Agency Breast Tumour Group; 15 March 2004.